drugset / Trial / NCT00423410
A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic effects of a novel anti-cancer drug, EPC2407, administered to patients with advanced cancer which have not responded to or have recurred following treatment with available therapies
Timeline
- Start
- 2006-12
- Primary completion
- 2009-04
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crolibulin | Small molecule | — | Intravenous |
Indications
No indication recorded.